🔗 Share this article

Given that the United States continues making historic revisions to its vaccine guidelines, one figure appears somewhat surprisingly: Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about coronavirus shots during the pandemic and has focused upon possible deaths following COVID-19 immunization in her recent time at the FDA.

Proposed Shifts to Childhood Immunization Schedule

Agency leaders had intended to reveal sweeping changes to the childhood vaccine schedule in December, bringing the US with the Danish immunization schedule, it is understood – a significant shift that would place the US at odds with much of the global community with insufficient data for benefit. The planned update has been delayed until the next year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to present at the gathering. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to run the division this calendar year.

A New Direction at the FDA

The acting appointment could signify a tighter collaboration between the drug and biologics centers as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing certain pediatric shot schedules in the US in order to be more similar to the Danish model, a society with nationalized medicine and a citizenry about the size of the state of Wisconsin.

In her initial public appearances, she has continued to focus on vaccines – traditionally the domain of Dr. Prasad, director of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Concerns Over Background

The appointee has little discernible background in pharmaceutical research, approval processes or leadership, which has been standard for previous heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the agency head and CBER since March.

“She appears not to have the requisite experience” for overseeing the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She has not conducted a scientific study. She is not versed in managing a large organization. She is not an expert in industry regulation.”

Past directors of the center would “understand legal statutes and the science of pharmaceutical innovation”, commented a former acting FDA commissioner. “Clearly, she doesn’t have the kind of background that prior appointees who headed CBER have had.”

CDER has an vast workload at the agency, the former commissioner pointed out.

“Many people just zeroes in on the innovative therapies, but the generic drug division clears a multitude of off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and other areas, and all of those must be looked after,” she explained. “The responsibility you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a major leadership aspect to the job, which oversees in excess of 5,000 staff members. “It is a enormous administrative position, if you execute it properly,” the former official added.

Official Statement and Disputed Initiatives

Regarding concerns about Høeg’s qualifications and whether this assignment represents increased cooperation among agency officials on immunizations, a spokesperson stated that the “questions stem from inaccurate assumptions”.

“This background aligns with the duties of her role,” the official said, noting the period Høeg spent guiding the FDA commissioner on “medication safety and approval science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg inherits the agency head's controversial expedited review system, a disputed rapid therapy clearance system that apparently troubled her predecessors. “By what process are these drugs being chosen for this voucher program? Who is making the choices?” Howard questioned. “There is a lot of lack of transparency happening at the FDA right now.”

In general, he stated, “the agency seems to be moving towards more relaxed rules of all drugs, with the exception of vaccines.”

Public Track Record on Vaccines

Regarding vaccines, Dr. Høeg has a more documented, if problematic, past, some experts observe. She released a study using non-validated public submissions to determine the incidence of heart inflammation after COVID-19 immunization. She consulted for the Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to imply Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the new federal leadership encompassed revising regulations for new vaccines and halting “non-essential” vaccines, she remarked post-election on a audio program. At the FDA, Dr. Høeg has reportedly floated the idea of barring teenage boys from obtaining Covid vaccines.

“She is an thorough true believer who starts off with her preconceived notions and reverse-engineers to accommodate the science in a highly misleading, untruthful fashion,” Howard argued.

Gaining Influence and a “Campaign of Retribution”

Høeg aligned with fellow dissenters, {like|